Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.1219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Jong Hoon Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Epirubicin, Nephroureterectomy, Urinary Bladder Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: HSRD VA.
Abstract (Originalsprache)
Purpose
We aimed to assess the effectiveness of early single intravesical administration of epirubicin in preventing intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.Materials and Methods Patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy between November 2018 and May 2022 were retrospectively reviewed. Intravesical epirubicin was administered within 48 hours if no evidence of leakage was observed. Epirubicin (50 mg) in 50 mL normal saline solution was introduced into the bladder via a catheter and maintained for 60 minutes. The severity of adverse events was graded using the Clavien-Dindo classification. We compared intravesical recurrence rate between the two groups. Multivariate analyses were performed to identify the independent predictors of bladder recurrence following radical nephroureterectomy.
Results
Epirubicin (n=55) and control (n=116) groups were included in the analysis. No grade 1 or higher bladder symptoms have been reported. A statistically significant difference in the intravesical recurrence rate was observed between the two groups (11.8% at 1 year in the epirubicin group vs. 28.4% at 1 year in the control group; log-rank p=0.039). In multivariate analysis, epirubicin instillation (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.20 to 0.93; p=0.033) and adjuvant chemotherapy (HR, 0.29; 95% CI, 0.13 to 0.65; p=0.003) were independently predictive of a reduced incidence of bladder recurrence.
Conclusion
This retrospective review revealed that a single immediate intravesical instillation of epirubicin is safe and can reduce the incidence of intravesical recurrence after radical nephroureterectomy. However, further prospective trials are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- HSRD VA
Zitieren
APA
Lee, J. H., Lee, C. U., Chung, J. H., Song, W., Kang, M., Jeon, H. G., Jeong, B. C., Seo, S. I., Jeon, S. S., & Sung, H. H. (2024). Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1219
Vancouver
Lee JH, Lee CU, Chung JH, Song W, Kang M, Jeon HG, et al. Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1219
BibTeX
@article{Lee2024,
author = {Lee, Jong Hoon and Lee, Chung Un and Chung, Jae Hoon and Song, Wan and Kang, Minyong and Jeon, Hwang Gyun and Jeong, Byong Chang and Seo, Seong Il and Jeon, Seong Soo and Sung, Hyun Hwan},
title = {Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.1219}
}
EUVIMED